Tolerability of MICARDISPLUS®
Like MICARDIS®, MICARDISPLUS® is well tolerated. The addition of HCTZ to telmisartan in MICARDISPLUS® does not compromise the safety profile, with MICARDISPLUS® also demonstrating a similar tolerability profile to placebo.1,2
/Graph14.jpg "Click to enlarge")
Tolerability of MICARDISPLUS® (telmisartan/hydrochlorothiazide [HCTZ]) compared with placebo and single-agent therapy
| Frequency of adverse events experienced by ≥ 2% of study population (% of patients) | ||||
|
|
Placebo (n=74) |
Telmisartan/HCTZ (n=414) | Telmisartan (n=209) |
HCTZ (n=121) |
| Upper respiratory tract infection | 6.8 | 8.0 | 7.2 | 9.9 |
| Dizziness | 1.4 | 5.1 | 3.8 | 5.8 |
| Headache | 16.2 | 4.1 | 7.2 | 9.1 |
| Sinusitis | 2.7 | 4.1 | 2.9 | 5.8 |
| Diarrhea | 0.0 | 3.4 | 5.3 | 1.7 |
| Fatigue | 1.4 | 3.4 | 2.9 | 2.5 |
| Pain | 6.8 | 2.4 | 3.8 | 4.1 |
| Back pain | 0.0 | 1.7 | 3.8 | 2.5 |
| Flu-like symptoms | 1.4 | 2.2 | 1.9 | 2.5 |
| Urinary tract infection | 2.7 | 1.7 | 1.9 | 2.5 |
| Insomnia | 4.1 | 0.5 | 0.5 | 2.5 |
| Hypokalaemia | 0.0 | 1.0 | 0.0 | 4.1 |
Calendar
Tools and Downloads
- Clinical Abstract Library
- Expert Interview Library
- ONTARGET® Results Webcast
- Free ONTARGET® Online Publication Download
- Cardiovascular Risk Guidelines
- Renin Angiotensin System in Cardiovascular Medicine Journal
My Alerts
You will shortly be able to create your own personal alerts service bringing the latest MICARDIS® news and updates direct to your inbox. Watch this space for more information.
